The Sexually Transmitted Diseases Diagnostics Market is expected to escalate at a CAGR of 7.9%, from US$ 3.8 billion in 2022 to US$ 6.4 billion through 2032.
The COVID-19 pandemic is a global health threat unmatched by anything that has occurred before, and its impact on sexually transmitted diseases testing is expected to be dire. As a result of disruptions in health care and sexually transmitted infections testing services during the first months of the COVID-19 pandemic, reports the CDC, there were fewer reports of sexually transmitted infections. In some cases, people spread infections unintentionally due to limited access to testing and diagnosis. Infection rates have returned to normal as clinics reopen.
Among the sexually transmitted diseases diagnostic testing types, the market is divided into those for chlamydia, syphilis, gonorrhoea, herpes simplex virus, human papillomavirus and human immunodeficiency virus.
Download Sample Report to learn about recent in the Sexually Transmitted Diseases Diagnostics Market observed by FMI. @ https://www.futuremarketinsights.com/reports/sample/rep-gb-14744
The list of Key Players are:
- Abbott Laboratories
- Bio-Rad laboratories
- Qaigen Inc.
- Diasorin SPA
- MedMira Inc.
- Hoffman
- Hologic
- Cepheid
- BioMeriuex
Growth in the sexually transmitted diseases diagnostics market is expected to be driven by a number of factors, including an increase in sexually transmitted diseases prevalence globally, patient awareness through education campaigns, and government initiatives.
The prevalence and incidents of sexually transmitted diseases have increased significantly over the past decade. In light of the increase in prevalence, many countries are focusing on expanding the reach of sexually transmitted diseases diagnosis by implementing national screening programs. Payment policies for these services are also favourable. Global sexually transmitted diseases testing is growing as a consequence of these factors.
KEY TAKEAWAYS:
- The sexually transmitted diseases diagnostics market is predicted to develop at a CAGR of 7.2% through 2032 in the laboratory testing section of the location of diagnostic test category.
- The CAGR for the laboratory devices segment of the devices category in diagnostics of sexually transmitted diseases is anticipated to be 7.1% through 2032.
- In the United States, the sexually transmitted diseases diagnostics market is estimated to reach US$ 2.3 billion by 2032, rising at a CAGR of 7.7% throughout the forecast period.
- By 2032, the market in the United Kingdom is expected to be valued at US$ 265.1 million, with a CAGR of 6.7% through 2032.
- With a CAGR of 7.2% throughout the forecast period, China is expected to reach a market size of US$ 442.0 million in the sexually transmitted diseases diagnostics market by 2032.
- By 2032, the sexually transmitted diseases diagnostics market in Japan is estimated to be worth US$ 356.4 million, growing at an annual rate of 6.3% through 2032.
- With a CAGR of 5.7% throughout the forecast period, South Korea is predicted to reach a market size of US$ 222.4 million in sexually transmitted disease diagnostics by 2032.
Ready to Dive In? Request Methodology! @
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-14744
COMPETITIVE LANDSCAPE:
Key companies profiled in the market report include Abbott Laboratories, Becton Dickinson Company, BioMérieux, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Diasorin Molecular LLC, Hologic, Inc., Orasure Technologies, Inc., Roche Holding AG, and Thermo Fisher Scientific Inc.
Sexually transmitted diseases diagnostics demand is largely in the North American market due to the availability of FDA-approved advanced test devices and the widespread use of public healthcare plans, which facilitate healthcare awareness.
Owing to the prevalence of sexually transmitted infections in underdeveloped countries and Asia-Pacific’s economic prosperity, this region should see significant growth during the forecast period of 2021 to 2028.
Key Players
- Abbott Laboratories
- Bio-Rad laboratories
- Qaigen Inc.
- Diasorin SPA
- MedMira Inc.
- F.Hoffman
- Hologic
- Cepheid
- BioMeriuex
Segments
By Types of Diseases:
- Gonorrhea
- Syphilis
- Chlamydia
- Herpes simple virus
- Human papillomavirus
- Others
By Diagnostic Test:
- Cultural/Isolated Organisms
- Molecular Test
- Immunology Assay
- Other types of testing
By Device:
- Laboratory Devices
- Thermal Cyclers-PCR
- Lateral Flow Readers Immunochromatographic Assay Flow Cytometers
- Absorbance Microplate Readers Enzyme-Linked Immunosorbent Assay
- Others
- Point of Sales
- Phone Chips
- Portable/Bench
- Diagnostic Kits
By Location:
- Laboratory
- Point of Care
By Region:
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- Latin America
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
